MRSO (TSE:5619) Debt-to-EBITDA : N/A (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:5619 MRSO Inc TSE:5619
40 GF Score
Price 円905.00
GF Value 円668.03
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is MRSO Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

MRSO's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was 円0 Mil. MRSO's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was 円0 Mil. MRSO's annualized EBITDA for the quarter that ended in Jun. 2026 was 円0 Mil.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for MRSO's Debt-to-EBITDA or its related term are showing as below:

TSE:5619' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.05   Med: 0.03   Max: 0.05
Current: -0.05

During the past 5 years, the highest Debt-to-EBITDA Ratio of MRSO was 0.05. The lowest was -0.05. And the median was 0.03.

TSE:5619's Debt-to-EBITDA is ranked worse than
100% of 479 companies
in the Healthcare Providers & Services industry
Industry Median: 2.19 vs TSE:5619: -0.05

MRSO  (TSE:5619) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

MRSO Debt-to-EBITDA Related Terms

MRSO Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for MRSO's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MRSO Debt-to-EBITDA Chart

MRSO Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
0.03 0.02 0.03 0.05 0.00

MRSO Quarterly Data
Dec21 Dec22 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.04 0.00 0.00 N/A

TSE:5619 vs VEEV, BTSG, HQY: Debt-to-EBITDA Comparison

For the Health Information Services subindustry, MRSO's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MRSO Debt-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, MRSO's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where MRSO's Debt-to-EBITDA falls into.


TSE:5619
40GF Score
MRSO Inc TSE:5619
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MRSO Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

MRSO's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -29.512
=0.00

MRSO's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is MRSO (TSE:5619) Overvalued in 2026?

Based on GuruFocus' analysis, MRSO stock appears to be overvalued. The current stock price of 円905.00 is trading 35.5% above its estimated GF Value™ of 円668.03. GuruFocus considers MRSO to be Significantly Overvalued.

Key valuation signals for TSE:5619:

  • Debt-to-EBITDA: N/A
  • GF Value™: 円668.03 vs. price of 円905.00 (35.5% above fair value)
  • GF Score™: 40/100 with 3 warning signs

No single metric tells the full story. See the TSE:5619 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MRSO Business Description

Address Shiroyama Trust Tower 17th floor, 4-3-1 Toranomon, Minato-ku, Tokyo, JPN, 105-6017
MRSO Inc operates a healthcare platform and provides vertical SaaS solutions for medical institutions, government entities, and corporations. The company offers a preventive medical platform that enables reservations for medical checkups and various cancer screenings. It also provides administrative DX services that support tasks carried out by local governments, including the acceptance of reservations for resident health checkups and vaccinations. These administrative DX services are used by local governments across regions with varying population sizes.
40GF Score

Get the complete analysis for TSE:5619

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円905.00
Price
円668.03
GF Value